Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259477 | 0.88 | ALDH1A1 (0.38) | CYP1A2ALDH1A1LMNACYP3A4SMN1; SMN2 | |
| SCHEMBL7944453 | 0.84 | L3MBTL1 (0.40) | CYP1A2ALDH1A1LMNACYP3A4SMN1; SMN2 | |
| Water SCHEMBL7944374 | 0.83 | L3MBTL1 (0.39) | CYP1A2ALDH1A1LMNACYP3A4SMN1; SMN2 | |
| SCHEMBL7952492 | 0.83 | ALDH1A1 (0.38) | CYP1A2ALDH1A1LMNACYP3A4SMN1; SMN2 | |
| SCHEMBL7944051 | 0.82 | CA12 (0.39) | CYP1A2ALDH1A1LMNACYP3A4SMN1; SMN2 | |
| SCHEMBL721297 | 0.82 | ABCC8 (0.56) | CYP1A2ALDH1A1LMNACYP3A4SMN1; SMN2 | |
| SCHEMBL4261657 | 0.81 | TRPA1 (0.37) | CYP1A2ALDH1A1LMNACYP3A4SMN1; SMN2 | |
| SCHEMBL7952627 | 0.80 | HCAR3 (0.46) | CYP1A2ALDH1A1LMNACYP3A4SMN1; SMN2 | |
| SCHEMBL7952052 | 0.78 | HTT (0.45) | CYP1A2ALDH1A1CYP3A4SMN1; SMN2ABCC8 | |
| SCHEMBL7953046 | 0.78 | CA1 (0.35) | CYP1A2ALDH1A1LMNACYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1222910-A | 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof | NOVO NORDISK AS (DK) | 1999-07-14 | — | — | CN | claimed |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-11-22 | — | — | US | disclosed |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-11 | — | — | US | disclosed |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2017-01-05 | — | — | US | disclosed |
| EP-3099304-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | Mayo Foundation for Medical Education and Research (US) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015117024-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-6242443-B1 | 1,2,4-benzothiadiazine derivatives, their preparation and use | NOVO NORDISK AIS (DK) | 2001-06-05 | — | — | US | disclosed |
| CN-1222910-A | 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof | NOVO NORDISK AS (DK) | 1999-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | CYP1A2 3075/4885ALDH1A1 1698/4885LMNA 2299/4885 |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | CYP1A2 3716/4885ALDH1A1 2055/4885LMNA 2005/4885 |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | CYP1A2 2573/4885ALDH1A1 943/4885LMNA 2093/4885 |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNK4, KCNK2 | CYP1A2 3097/4885ALDH1A1 1014/4885LMNA 2066/4885 |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | CYP1A2 2573/4885ALDH1A1 943/4885LMNA 2093/4885 |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | CYP1A2 2573/4885ALDH1A1 943/4885LMNA 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.